Log In
BCIQ
Print this Print this
 

lidocaine/tetracaine (Pliaglis)

  Manage Alerts
Collapse Summary General Information
Company Nuvo Pharmaceuticals Inc.
DescriptionPhase-changing topical formulation of lidocaine and tetracaine
Molecular Target Sodium channel voltage-dependent
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationAnesthesia
Indication DetailsNumb the skin before various medical procedures; Produce local anaesthesia on intact skin in adults prior to superficial dermatological procedures
Regulatory Designation
PartnerCrescita Therapeutics Inc.;
Galderma S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$36.6M

$0.2M

$23.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/23/2011

$36.6M

$0.2M

$23.6M

Get a free BioCentury trial today